ARDX
Price
$6.89
Change
-$0.15 (-2.13%)
Updated
Jan 14 closing price
Capitalization
1.67B
55 days until earnings call
Intraday BUY SELL Signals
CLRB
Price
$3.75
Change
-$0.30 (-7.43%)
Updated
Jan 14 closing price
Capitalization
15.88M
Intraday BUY SELL Signals
Interact to see
Advertisement

ARDX vs CLRB

Header iconARDX vs CLRB Comparison
Open Charts ARDX vs CLRBBanner chart's image
Ardelyx
Price$6.89
Change-$0.15 (-2.13%)
Volume$3.28M
Capitalization1.67B
Cellectar Biosciences
Price$3.75
Change-$0.30 (-7.43%)
Volume$197.43K
Capitalization15.88M
ARDX vs CLRB Comparison Chart in %
View a ticker or compare two or three
VS
ARDX vs. CLRB commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a Hold and CLRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ARDX: $6.89 vs. CLRB: $3.74)
Brand notoriety: ARDX and CLRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 83% vs. CLRB: 201%
Market capitalization -- ARDX: $1.67B vs. CLRB: $15.88M
ARDX [@Biotechnology] is valued at $1.67B. CLRB’s [@Biotechnology] market capitalization is $15.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 0 FA rating(s) are green whileCLRB’s FA Score has 0 green FA rating(s).

  • ARDX’s FA Score: 0 green, 5 red.
  • CLRB’s FA Score: 0 green, 5 red.
According to our system of comparison, ARDX is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 5 TA indicator(s) are bullish while CLRB’s TA Score has 7 bullish TA indicator(s).

  • ARDX’s TA Score: 5 bullish, 4 bearish.
  • CLRB’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, CLRB is a better buy in the short-term than ARDX.

Price Growth

ARDX (@Biotechnology) experienced а +18.18% price change this week, while CLRB (@Biotechnology) price change was +12.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

ARDX is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARDX($1.67B) has a higher market cap than CLRB($15.9M). CLRB YTD gains are higher at: 26.949 vs. ARDX (18.182). ARDX has higher annual earnings (EBITDA): -26.22M vs. CLRB (-29.8M). ARDX has more cash in the bank: 243M vs. CLRB (12.6M). CLRB has less debt than ARDX: CLRB (432K) vs ARDX (208M). ARDX has higher revenues than CLRB: ARDX (398M) vs CLRB (0).
ARDXCLRBARDX / CLRB
Capitalization1.67B15.9M10,516%
EBITDA-26.22M-29.8M88%
Gain YTD18.18226.94967%
P/E RatioN/AN/A-
Revenue398M0-
Total Cash243M12.6M1,929%
Total Debt208M432K48,148%
FUNDAMENTALS RATINGS
ARDX vs CLRB: Fundamental Ratings
ARDX
CLRB
OUTLOOK RATING
1..100
2222
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
99100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3864
P/E GROWTH RATING
1..100
4776
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLRB's Valuation (70) in the Biotechnology industry is in the same range as ARDX (100). This means that CLRB’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's Profit vs Risk Rating (99) in the Biotechnology industry is in the same range as CLRB (100). This means that ARDX’s stock grew similarly to CLRB’s over the last 12 months.

ARDX's SMR Rating (97) in the Biotechnology industry is in the same range as CLRB (100). This means that ARDX’s stock grew similarly to CLRB’s over the last 12 months.

ARDX's Price Growth Rating (38) in the Biotechnology industry is in the same range as CLRB (64). This means that ARDX’s stock grew similarly to CLRB’s over the last 12 months.

ARDX's P/E Growth Rating (47) in the Biotechnology industry is in the same range as CLRB (76). This means that ARDX’s stock grew similarly to CLRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXCLRB
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 7 days ago
87%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ARDX
Daily Signal:
Gain/Loss:
CLRB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IZM1.670.27
+19.29%
ICZOOM Group
CGBD12.810.28
+2.23%
Carlyle Secured Lending
QTWO68.78-0.03
-0.04%
Q2 Holdings
CRDF2.81-0.06
-2.09%
Cardiff Oncology
MLM636.71-29.00
-4.36%
Martin Marietta Materials

ARDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
-2.13%
VCYT - ARDX
45%
Loosely correlated
-1.39%
PCVX - ARDX
35%
Loosely correlated
+5.41%
RNAC - ARDX
35%
Loosely correlated
-0.26%
MNOV - ARDX
32%
Poorly correlated
-0.69%
CLRB - ARDX
31%
Poorly correlated
-7.30%
More

CLRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLRB has been loosely correlated with QTTB. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CLRB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
-7.30%
QTTB - CLRB
61%
Loosely correlated
+6.82%
ADCT - CLRB
41%
Loosely correlated
+0.27%
HOTH - CLRB
39%
Loosely correlated
-0.48%
CELC - CLRB
37%
Loosely correlated
+9.86%
ANAB - CLRB
36%
Loosely correlated
+4.44%
More